Jayvardhan Pandit

发表

Design of selective, ATP-competitive inhibitors of Akt.

Tracey Clark, Matthew Marx, Blaise Lippa, 2010, Journal of medicinal chemistry.

6-amino-4-(pyrimidin-4-yl)pyridones: novel glycogen synthase kinase-3β inhibitors.

Matthew D. Wessel, J. Pandit, M. Wessel, 2011, Bioorganic & medicinal chemistry letters.

Theoretical and experimental design of atypical kinase inhibitors: application to p38 MAP kinase.

Dennis E Danley, P. Lemotte, M. Mansour, 2005, Journal of medicinal chemistry.

Discovery of cytotoxic dolastatin 10 analogues with N-terminal modifications.

Frank Loganzo, Carolyn A Leverett, Chakrapani Subramanyam, 2014, Journal of medicinal chemistry.

Mechanism for the allosteric regulation of phosphodiesterase 2A deduced from the X-ray structure of a near full-length construct

K. Fennell, J. Pandit, F. Menniti, 2009, Proceedings of the National Academy of Sciences.

Synthesis and structure based optimization of novel Akt inhibitors.

Tracey Clark, Blaise Lippa, J. Pandit, 2008, Bioorganic & medicinal chemistry letters.

Discovery of a novel class of phosphodiesterase 10A inhibitors and identification of clinical candidate 2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920) for the treatment of schizophrenia.

Spiros Liras, Anne W. Schmidt, J. Pandit, 2009, Journal of medicinal chemistry.

Discovery of a novel series of 6-azauracil-based thyroid hormone receptor ligands: potent, TR beta subtype-selective thyromimetics.

Peter Cornelius, Eunsun Lee, Dennis E Danley, 2003, Bioorganic & medicinal chemistry letters.

Discovery and optimization of a novel spiropyrrolidine inhibitor of β-secretase (BACE1) through fragment-based drug design.

M. Mansour, J. Pandit, BinQing Wei, 2012, Journal of medicinal chemistry.

Discovery of a series of 6,7-dimethoxy-4-pyrrolidylquinazoline PDE10A inhibitors.

Spiros Liras, Meihua Tu, J. Pandit, 2007, Journal of medicinal chemistry.

Synthesis and biological activity of selective pipecolic acid-based TNF-alpha converting enzyme (TACE) inhibitors.

Dennis E Danley, D. Danley, G. Schulte, 2002, Bioorganic & medicinal chemistry letters.

Application of Structure-Based Design and Parallel Chemistry to Identify a Potent, Selective, and Brain Penetrant Phosphodiesterase 2A Inhibitor.

Laura McDowell, Scot Mente, Mihaly Hajos, 2017, Journal of medicinal chemistry.

Discovery of potent, selective, bioavailable phosphodiesterase 2 (PDE2) inhibitors active in an osteoarthritis pain model, part I: transformation of selective pyrazolodiazepinone phosphodiesterase 4 (PDE4) inhibitors into selective PDE2 inhibitors.

Howard Miller, J. Pandit, C. Whitehead, 2013, Bioorganic & medicinal chemistry letters.

Discovery of Cytotoxic Dolastatin 10 Analogues with N-Terminal Modifications

Sai Chetan K. Sukuru, Frank Loganzo, Michael J. Shapiro, 2015 .